OBJECTIVES: The objective of the study was to analyse key HIV-related outcomes in migrants originating from Latin America and the Spanish-speaking Caribbean (LAC) or sub-Saharan Africa (SSA) living in Spain compared with native Spaniards (NSP). METHODS: The Cohort of the Spanish AIDS Research Network (CoRIS) is an open, prospective, multicentre cohort of antiretroviral-naïve patients representing 13 of the 17 Spanish regions. The study period was 2004-2010. Multivariate logistic or Fine and Gray regression models were fitted as appropriate to estimate the adjusted effect of region of origin on the different outcomes. RESULTS: Of the 6811 subjects in CoRIS, 6278 were NSP (74.2%), LAC (19.4%) or SSA (6.4%). For these patients, the follow-up time was 15870 person-years. Compared with NSP, SSA and LAC under 35 years of age had a higher risk of delayed diagnosis [odds ratio (OR) 2.0 (95% confidence interval (CI) 1.5-2.8) and OR 1.7 (95% CI 1.4-2.1), respectively], as did LAC aged 35-50 years [OR 1.3 (95% CI 1.0-1.6)]. There were no major differences in time to antiretroviral therapy (ART) requirement or initiation. SSA exhibited a poorer immunological and virological response [hazard ratio (HR) [corrected] 0.8 (95% CI 0.7-1.0) and HR [corrected] 0.7 (95% CI 0.6-0.9), respectively], while no difference was found for LAC. SSA and LAC showed an increased risk of AIDS for ages between 35 and 50 years [HR 2.0 (95% CI 1.1-3.7) and HR [corrected] 1.6 (95% CI 1.1-2.4), respectively], which was attributable to a higher incidence of tuberculosis. However, no statistically significant differences were observed in mortality. CONCLUSIONS: Migrants experience a disproportionate diagnostic delay, but no meaningful inequalities were identified regarding initiation of treatment after diagnosis. A poorer virological and immunological response was observed in SSA. Migrants had an increased risk of AIDS, which was mainly attributable to tuberculosis.
OBJECTIVES: The objective of the study was to analyse key HIV-related outcomes in migrants originating from Latin America and the Spanish-speaking Caribbean (LAC) or sub-Saharan Africa (SSA) living in Spain compared with native Spaniards (NSP). METHODS: The Cohort of the Spanish AIDS Research Network (CoRIS) is an open, prospective, multicentre cohort of antiretroviral-naïve patients representing 13 of the 17 Spanish regions. The study period was 2004-2010. Multivariate logistic or Fine and Gray regression models were fitted as appropriate to estimate the adjusted effect of region of origin on the different outcomes. RESULTS: Of the 6811 subjects in CoRIS, 6278 were NSP (74.2%), LAC (19.4%) or SSA (6.4%). For these patients, the follow-up time was 15870 person-years. Compared with NSP, SSA and LAC under 35 years of age had a higher risk of delayed diagnosis [odds ratio (OR) 2.0 (95% confidence interval (CI) 1.5-2.8) and OR 1.7 (95% CI 1.4-2.1), respectively], as did LAC aged 35-50 years [OR 1.3 (95% CI 1.0-1.6)]. There were no major differences in time to antiretroviral therapy (ART) requirement or initiation. SSA exhibited a poorer immunological and virological response [hazard ratio (HR) [corrected] 0.8 (95% CI 0.7-1.0) and HR [corrected] 0.7 (95% CI 0.6-0.9), respectively], while no difference was found for LAC. SSA and LAC showed an increased risk of AIDS for ages between 35 and 50 years [HR 2.0 (95% CI 1.1-3.7) and HR [corrected] 1.6 (95% CI 1.1-2.4), respectively], which was attributable to a higher incidence of tuberculosis. However, no statistically significant differences were observed in mortality. CONCLUSIONS: Migrants experience a disproportionate diagnostic delay, but no meaningful inequalities were identified regarding initiation of treatment after diagnosis. A poorer virological and immunological response was observed in SSA. Migrants had an increased risk of AIDS, which was mainly attributable to tuberculosis.
Authors: Julie H Levison; Margarita Alegría; Ye Wang; Sheri L Markle; Larmiar Fuentes; Dianna L Mejia; Andrew Tarbox; Lucía Albarracín García; Lucía Cellerino; Nabila El-Bassel Journal: AIDS Behav Date: 2019-04
Authors: Donna M Tilley; Elizabeth Griggs; Jennifer Hoy; Stephen T Wright; Ian Woolley; Michael Burke; Catherine C O'Connor Journal: AIDS Care Date: 2015
Authors: G Sulis; I El Hamad; M Fabiani; S Rusconi; F Maggiolo; G Guaraldi; G Bozzi; C Bernardini; M Lichtner; C Stentarelli; L Carenzi; D Francisci; A Saracino; F Castelli Journal: Infection Date: 2014-06-29 Impact factor: 3.553
Authors: J Reyes-Urueña; C Campbell; C Hernando; N Vives; C Folch; L Ferrer; L Fernández-López; A Esteve; J Casabona Journal: Epidemiol Infect Date: 2017-03-08 Impact factor: 4.434
Authors: Laure-Amélie de Monteynard; Rosemary Dray-Spira; Pierre de Truchis; Sophie Grabar; Odile Launay; Jean-Luc Meynard; Marie-Aude Khuong-Josses; Jacques Gilquin; David Rey; Anne Simon; Juliette Pavie; Aba Mahamat; Sophie Matheron; Dominique Costagliola; Sophie Abgrall Journal: PLoS One Date: 2015-03-03 Impact factor: 3.240
Authors: Belén Alejos; Victoria Hernando; Jose Iribarren; Juan Gonzalez-García; Asuncion Hernando; Jesus Santos; Victor Asensi; Ana Gomez-Berrocal; Julia Del Amo; Inma Jarrin Journal: Medicine (Baltimore) Date: 2016-09 Impact factor: 1.889
Authors: Jessika Deblonde; André Sasse; Julia Del Amo; Fiona Burns; Valerie Delpech; Susan Cowan; Michele Levoy; Lilana Keith; Anastasia Pharris; Andrew Amato-Gauci; Teymur Noori Journal: BMC Public Health Date: 2015-12-10 Impact factor: 3.295
Authors: Debora Alvarez-Del Arco; Susana Monge; Ana M Caro-Murillo; Oriana Ramírez-Rubio; Amaya Azcoaga-Lorenzo; Maria J Belza; Yaiza Rivero-Montesdeoca; Teymur Noori; Julia Del Amo Journal: Eur J Public Health Date: 2013-08-05 Impact factor: 3.367
Authors: D Van Beckhoven; E Florence; J Ruelle; J Deblonde; C Verhofstede; S Callens; E Vancutsem; P Lacor; R Demeester; J-C Goffard; A Sasse Journal: BMC Infect Dis Date: 2015-11-03 Impact factor: 3.090